Report data from Phase 3 NAVIGATOR study in patients with severe uncontrolled asthma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Apr 2020
- Due
- 31 Dec 2020
- Delivered
- November 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company reiterated its expectation of data from the Phase 3 NAVIGATOR study in patients with severe uncontrolled asthma by the end of 2020.”
What we found
Evidence strength A What the grades mean
Amgen announced positive top-line results from the Phase 3 NAVIGATOR study in November 2020, meeting the commitment to report data by the end of 2020.
-
A Amgen Inc. 10-K filed 2021-02-09
“In November 2020, we and AstraZeneca plc (AstraZeneca) announced positive top-line results from the registrational phase 3 NAVIGATOR trial in adults and adolescents with severe uncontrolled asthma.” ✓ confirmed on the page
Market reaction: the shares moved -0.4% against the S&P 500 over the three sessions around the disclosure (8 Feb 2021 to 11 Feb 2021). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 study data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Amgen Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-AMGN-002323 · Corrections policy